GlassScriptPhysician profile
Afaq Ahmad
NPI 1801933965
$2,863.48
in general payments reported to CMS, 2019-2025
11 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $164 · 2020: $111 · 2021: $96.41 · 2022: $1,958 · 2023: $229 · 2024: $180 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $346 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $345.68 |
| Education | $188.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,866.50 | 2022-2024 | Rybrevant |
| Csl Behring | $198.01 | 2020-2024 | Kcentra |
| Alexion Pharmaceuticals, INC. | $150.00 | 2019 | |
| Adc Therapeutics America, INC. | $125.00 | 2025 | |
| Eisai INC. | $124.20 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $119.70 | 2022 | |
| Amgen INC. | $95.00 | 2020 | |
| Seagen INC. | $89.95 | 2023 | |
| Janssen Pharmaceuticals, INC | $70.15 | 2019-2024 | Xarelto |
| Acrotech Biopharma INC. | $13.93 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Afaq Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.